Merck KGaA fails midphase lupus trial, says totality of data support further development
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded (PDF) further development is warranted in light of responses seen in subgroups and a recent win in another form of the disease.
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded (PDF) further development is warranted in light of responses seen in subgroups and a recent win in another form of the disease.
